Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=38624434
&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests
in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215
Prototype of a Smart Microfluidic Platform for the Evaluation of SARS-Cov-2
Pathogenesis, Along with Estimation of the Effectiveness of Potential Drug
Candidates and Antigen-Antibody Interactions in Convalescent Plasma Therapy
#MMPMID38624434
Roy N
; Kashyap J
; Verma D
; Tyagi RK
; Prabhakar A
Trans Indian Natl Acad Eng
2020[]; 5
(2
): 241-250
PMID38624434
show ga
Originating in China during December 2019, the novel corona-virus, SARS-CoV-2,
has created mayhem worldwide in a very short time. The outbreak has been so rapid
and widespread that the only option to treat the patients was administering drugs
already available in the market like chloroquine/hydroxychloroquine (an
antimalarial drug) and remedesivir. A large number of patients have been cured
but the attribution to survival by these drugs has been controversial. Till date,
we do not have any specific drug or vaccine available for COVID-19 and the
pandemic seems to be far from over. To handle the current challenges posed by the
outbreak effectively, we need to employ innovative interdisciplinary approaches.
Organ-on-chip (OOC), particularly lung-on-chip, is one such approach which
combines the potential of microfluidics, cell culture and molecular biology into
a single miniaturised platform. The device is realized to be capable of
simulating in-vivo physiological responses of an organ. In the current study, an
OOC, which is a multichannel 3D cell culture microfluidic device, is made via
soft lithography technique, using polydimethylsiloxane-polymer and diverse
polymeric porous/semipermeable membranes. Several polymer membranes i.e. PDMS,
polyvinylidene fluoride (PVDF), nitrocellulose, polyester etc., integrated into
the microdevices, were efficiently explored to realize their better cell-adhesion
and viability property. We also propose for the application of a simple, smart
and cost-effective lung-on-chip platform to study the SARS-CoV-2 pathogenesis in
humans, drug toxicity testing and provide insights into antigen-antibody
interactions. This platform will enable us to study multiple phenomena at a
micro-level generating more reliable data and a better understanding of the
underlying mechanisms of SARS-CoV-2 infection and pathogenesis.
free
free
free
